Compare Cassava Sciences Inc (FLNA) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? Cassava Sciences Inc trades at $0.71 (market cap $35.91M), while SS&C Technologies Holdings Inc. Common Stock trades at $82.08 (market cap $19.13B). The key difference: SS&C Technologies Holdings Inc. Common Stock is far larger — about 532.7× Cassava Sciences Inc's market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.47% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 38 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| FLNA | SSNC | |
|---|---|---|
Market Cap | $35.91M | $19.13B |
Volume | 323,246 | 1,333,448 |
Sector | Health | Technology |
52-Week High | $4.64 | $89.62 |
52-Week Low | $0.68 | $62.05 |
Typical Hold Time | 38 Days | 0 Days |
Enterprise Value | -$46.77M | $26.47B |
Dividend Yield | — | 1.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.7434, down 3.39% today, with a bearish technical signal despite oscillator bullishness. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates in recent quarters. Recent FDA approval to lift the clinical hold on simufilam for TSC-related epilepsy is a positive development, with Phase 2a trials expected in early 2027.
Outlook remains speculative given negative cash flows and lack of revenue, but analyst consensus is bullish with 67% buy ratings. Key risks include ongoing operational losses and dependence on clinical trial success. The stock presents high-risk biotech opportunity with potential upside from successful drug development.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
